Viridian Therapeutics, Inc./DE Accretion Expense
Viridian Therapeutics, Inc./DE (VRDN) reported Accretion Expense of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2022-03-11
- Viridian Therapeutics, Inc./DE accretion expense for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE accretion expense for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE accretion expense for the quarter ending 2020-12-31 was $125.00K, a 68.92% increase year-over-year.
- Viridian Therapeutics, Inc./DE accretion expense for the quarter ending 2020-03-31 was $63.00K, a 32.98% decline year-over-year.
- Viridian Therapeutics, Inc./DE accretion expense for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Viridian Therapeutics, Inc./DE accretion expense for fiscal 2020 was $263.00K, a 22.65% decline from fiscal 2019.
- Viridian Therapeutics, Inc./DE accretion expense for fiscal 2019 was $340.00K, a 9.57% decline from fiscal 2018.
- Viridian Therapeutics, Inc./DE accretion expense for fiscal 2018 was $376.00K, a 300.00% increase from fiscal 2017.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 10-K · filed 2022-03-11 | ||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | $125.00K derived: sum of 2 quarters · filed 2022-03-11 | ||
| 2020-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $263.00K 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $138.00K 10-Q · filed 2021-11-05 | |||
| 2020-03-31 | $63.00K 10-Q · filed 2021-05-07 | $137.00K derived: sum of 2 quarters · filed 2021-05-07 | $217.00K derived: sum of 3 quarters · filed 2021-05-07 | $309.00K derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | $154.00K derived: sum of 2 quarters · filed 2021-03-26 | $246.00K derived: sum of 3 quarters · filed 2021-03-26 | $340.00K 10-K · filed 2021-03-26 |
| 2019-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $172.00K derived: sum of 2 quarters · filed 2020-11-12 | $266.00K 10-Q · filed 2020-11-12 | $359.00K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $92.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $186.00K 10-Q · filed 2019-08-08 | $279.00K derived: sum of 3 quarters · filed 2020-05-08 | $373.00K derived: sum of 4 quarters · filed 2020-05-08 |
| 2019-03-31 | $94.00K 10-Q · filed 2020-05-08 | $187.00K derived: sum of 2 quarters · filed 2020-05-08 | $281.00K derived: sum of 3 quarters · filed 2020-05-08 | $374.00K derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $187.00K derived: sum of 2 quarters · filed 2020-03-13 | $280.00K derived: sum of 3 quarters · filed 2020-03-13 | $376.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $187.00K derived: sum of 2 quarters · filed 2019-11-08 | $283.00K 10-Q · filed 2019-11-08 | $292.00K derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $189.00K 10-Q · filed 2019-08-08 | $198.00K derived: sum of 3 quarters · filed 2019-08-08 | $222.00K derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $96.00K 10-Q · filed 2019-05-09 | $105.00K derived: sum of 2 quarters · filed 2019-05-09 | $129.00K derived: sum of 3 quarters · filed 2019-05-09 | $158.00K derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $33.00K derived: sum of 2 quarters · filed 2019-03-14 | $62.00K derived: sum of 3 quarters · filed 2019-03-14 | $94.00K 10-K · filed 2019-03-14 |
| 2017-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $53.00K derived: sum of 2 quarters · filed 2018-11-07 | $85.00K 10-Q · filed 2018-11-07 | $118.00K derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $61.00K 10-Q · filed 2018-08-08 | $94.00K derived: sum of 3 quarters · filed 2018-08-08 | $136.00K derived: sum of 4 quarters · filed 2018-08-08 |
| 2017-03-31 | $32.00K 10-Q · filed 2018-05-09 | $65.00K derived: sum of 2 quarters · filed 2018-05-09 | $107.00K derived: sum of 3 quarters · filed 2018-05-09 | $148.00K derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $75.00K derived: sum of 2 quarters · filed 2018-03-15 | $116.00K derived: sum of 3 quarters · filed 2018-03-15 | $158.00K 10-K · filed 2018-03-15 |
| 2016-09-30 | $42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $83.00K derived: sum of 2 quarters · filed 2017-11-09 | $125.00K 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $83.00K 10-Q · filed 2017-08-11 | ||
| 2016-03-31 | $42.00K 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |